Citation tools
"LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung." European Respiratory Journal
42.Suppl 57
(2013):
371.
Web. 18 April. 2024.